Ahrang Jung1, Matthew E Nielsen, Jamie L Crandell, Mary H Palmer, Ashley Leak Bryant, Sophia K Smith, Deborah K Mayer. 1. Author Affiliations: School of Nursing (Drs Jung, Crandell, Palmer, Bryant, and Mayer), School of Medicine (Dr Nielsen), and Lineberger Comprehensive Cancer Center (Drs Nielsen, Bryant, and Mayer), The University of North Carolina at Chapel Hill; and School of Nursing, Duke University, Durham, North Carolina (Dr Smith).
Abstract
BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) represents approximately 75% of newly diagnosed patients with bladder cancer. Non-muscle-invasive bladder cancer survivors have unique chronic burdens including frequent recurrences, repeated surveillance cystoscopies and treatments, and the highest lifetime medical cost per person among all cancers. OBJECTIVE: The purpose of this study was to summarize studies assessing quality of life (QOL) in NMIBC survivors. METHODS: The literature from January 2005 to March 2017 found in PubMed, CINAHL, and PsycINFO databases was reviewed systematically. Inclusion criteria were as follows: (1) research about NMIBC survivors, (2) outcomes included QOL, (3) original research article published in peer-reviewed journals, and (4) published in English. RESULTS: A total of 15 studies were included: 14 quantitative studies and 1 mixed-methods study. Non-muscle-invasive bladder cancer survivors had significantly lower QOL compared with the general population, especially in fatigue, physical and role functioning, and mental health. Repeated transurethral resections and intravesical treatments were associated with impaired physical function and mental health. Most NMIBC survivors had concerns of urinary and bowel problems and sexual function. CONCLUSION: Despite a good prognosis, NMIBC and its treatment have a significant impact on QOL in survivors. The findings showed large burdens in NMIBC survivors and suggest that further research is needed to better understand potential opportunities to improve QOL in this population. IMPLICATIONS FOR PRACTICE: Oncology nurses are in the critical position for assessing symptoms and concerns. Oncology nurses should pay special attention to NMIBC survivors who have unique symptoms and burden with the aim of improving survivors' QOL.
BACKGROUND:Non-muscle-invasive bladder cancer (NMIBC) represents approximately 75% of newly diagnosed patients with bladder cancer. Non-muscle-invasive bladder cancer survivors have unique chronic burdens including frequent recurrences, repeated surveillance cystoscopies and treatments, and the highest lifetime medical cost per person among all cancers. OBJECTIVE: The purpose of this study was to summarize studies assessing quality of life (QOL) in NMIBC survivors. METHODS: The literature from January 2005 to March 2017 found in PubMed, CINAHL, and PsycINFO databases was reviewed systematically. Inclusion criteria were as follows: (1) research about NMIBC survivors, (2) outcomes included QOL, (3) original research article published in peer-reviewed journals, and (4) published in English. RESULTS: A total of 15 studies were included: 14 quantitative studies and 1 mixed-methods study. Non-muscle-invasive bladder cancer survivors had significantly lower QOL compared with the general population, especially in fatigue, physical and role functioning, and mental health. Repeated transurethral resections and intravesical treatments were associated with impaired physical function and mental health. Most NMIBC survivors had concerns of urinary and bowel problems and sexual function. CONCLUSION: Despite a good prognosis, NMIBC and its treatment have a significant impact on QOL in survivors. The findings showed large burdens in NMIBC survivors and suggest that further research is needed to better understand potential opportunities to improve QOL in this population. IMPLICATIONS FOR PRACTICE: Oncology nurses are in the critical position for assessing symptoms and concerns. Oncology nurses should pay special attention to NMIBC survivors who have unique symptoms and burden with the aim of improving survivors' QOL.
Authors: Ahrang Jung; Jamie L Crandell; Matthew E Nielsen; Sophia K Smith; Ashley Leak Bryant; Deborah K Mayer Journal: Support Care Cancer Date: 2022-04-18 Impact factor: 3.603
Authors: Ahrang Jung; Matthew E Nielsen; Jamie L Crandell; Mary H Palmer; Sophia K Smith; Ashley Leak Bryant; Deborah K Mayer Journal: BJU Int Date: 2019-09-25 Impact factor: 5.588
Authors: Kit Man Chan; Jonathan Gleadle; Jordan Li; Thomas Danny Michl; Krasimir Vasilev; Melanie MacGregor Journal: Sci Rep Date: 2021-03-31 Impact factor: 4.996
Authors: Wei Shen Tan; Chin Hai Teo; Delcos Chan; Kar Mun Ang; Malgorzata Heinrich; Andrew Feber; Rachael Sarpong; Norman Williams; Chris Brew-Graves; Chirk Jenn Ng; John Kelly Journal: BJU Int Date: 2020-02-12 Impact factor: 5.588